Rat cytomegalovirus infection depletes MHC II in bone marrow derived dendritic cells  by Baca Jones, Carmen C. et al.
Virology 388 (2009) 78–90
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roRat cytomegalovirus infection depletes MHC II in bone marrow derived
dendritic cells
Carmen C. Baca Jones a,b, Craig N. Kreklywich c, Ilhem Messaoudi a,b, Jennifer Vomaske a,b, Erin McCartney a,b,
Susan L. Orloff a,b,c,d, Jay A. Nelson a,b, Daniel N. Streblow a,b,⁎
a Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239, USA
b The Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA
c Department of Surgery, Oregon Health and Science University, Portland, OR 97239, USA
d Portland VA Medical Center, Portland, OR 97239, USA⁎ Corresponding author. Vaccine and Gene Therapy
Science University, 505 SW 185th, Beaverton, OR 97006
E-mail address: streblow@ohsu.edu (D.N. Streblow)
0042-6822/$ – see front matter © 2009 Elsevier Inc. A
doi:10.1016/j.virol.2009.02.050a b s t r a c ta r t i c l e i n f oArticle history:
Received 12 November 2008
Returned to author for revision
22 December 2008
Accepted 28 February 2009
Available online 5 April 2009
Keywords:
Dendritic cells
Viral
MHC
Antigen presentation/processing
CytomegalovirusWhile cytomegalovirus (CMV) infects and replicates in a multitude of cell types, the ability of the virus to
replicate in antigen presenting cells (APCs) is believed to play a critical role in the viral dissemination and
latency. CMV infection of APCs and manipulation of their function are important areas of investigation. CMV
down regulation of MHC II is reportedly mediated by the HCMV proteins US2, US3, UL83, UL111a (vIL10) or
through the induction of cellular IL10. In this study, we demonstrate that rat CMV (RCMV) signiﬁcantly
reduces MHC II expression neither by mechanisms that do not involve orthologues of the known HCMV
genes nor by an increase in cellular IL10. Rat bone marrow derived dendritic cells (BMDC) were highly
susceptible to infection with RCMV and a recombinant RCMV expressing eGFP. RCMV infection of BMDCs
depleted both surface and intracellular MHC II to nearly undetectable levels as well as reduced surface
expression of MHC I. The effect on MHC II only occurred in the infected GFP positive cells and is mediated by
an immediate early or early viral gene product. Furthermore, treatment of uninfected immature DCs with
virus-free conditioned supernatants from infected cells failed to down regulate MHC II. RCMV depletion of
MHC II was sensitive to treatment with lysosomal inhibitors but not proteasomal inhibitors suggesting that
the mechanism of RCMV-mediated down regulation of MHC II occurs through endocytic degradation. Since
RCMV does not encode homologues of US2, US3, UL83 or UL111a, these data indicate a novel mechanism for
RCMV depletion of MHC II.© 2009 Elsevier Inc. All rights reserved.Introduction
Cytomegaloviruses (CMV) are ubiquitous, species-speciﬁc β-
herpesviruses. Between ﬁfty and 90% of adults worldwide are infected
with Human Cytomegalovirus (HCMV) (Mocarski, 2001). While
infection with HCMV is normally asymptomatic in the immunocom-
petent host, immunosuppressed individuals and neonates infected
with the virus may develop severe complications including pneumo-
nia, retinitis, gastrointestinal disease and death. Primary HCMV
infection typically results in life long persistence characterized by a
latent phase with intermittent reactivations and secondary infections
(Mocarski, 2001). The establishment of this persistent infection
provides a unique challenge to the virus, which is under constant
surveillance by the host immune system. CMVs derive their success in
maintaining their prevalence from their ability to evade immune
recognition and clearance through the acquisition of genes speciﬁcallyInstitute, Oregon Health and
, USA. Fax: +1 503 418 2719.
.
ll rights reserved.targeting both the adaptive and innate immune response. With a
coding capacity of approximately 180 predicted open reading frames,
only 40–60 of which have been demonstrated to be essential for in
vitro viral replication, it is estimated that nearly two thirds of the CMV
genome is devoted to sustaining infection in vivo, a prime component
of which is subversion of host immune surveillance (Dunn et al., 2003;
Mocarski, 2002).
The adaptive strategies employed by CMV to counteract the host
immune system fall into two broad categories: immunomodulation
and immune evasion. Examples of immunomodulation can be found
in viral recruitment of leukocytes to the site of primary infection
through the expression of virus-encoded chemokines and through
virus-induced expression of host cell cytokines and growth factors.
Dampening of the inﬂammatory response and virus-induced func-
tional paralysis of antigen presenting cells (APCs) such as dendritic
cells (DC) and macrophages occurs through the altered cytokine
proﬁles of infected cells as well as by the down regulation of host cell
receptors and ligands (Mocarski, 2002). While evasion strategies
implemented by CMV include the ability of the virus to maintain a
quiescent infection in APCs, the prevailing paradigm of immune
79C.C. Baca Jones et al. / Virology 388 (2009) 78–90evasion is typiﬁed by CMV manipulation of both the classical and
nonclassical major histocompatability complexes.
The capacity of APCs to present antigen in the context of MHC I and
II is central to the ability of the host to activate the adaptive immune
response to viral infection. Like other members of the herpesvirus
family, CMV has evolved to avoid host immune detection by
manipulating MHC processing and presentation (reviewed in Lilley
and Ploegh, 2005). Several ORFs have been identiﬁed in both mouse
CMV (MCMV) and HCMV that mediate MHC I down regulation at
various stages of MHC processing. Three MCMV ORFs, m4, m6 and
m152, encode glycoproteins with nonredundant and complementary
function in MHC I interference (Kavanagh et al., 2001a). M4 binds
MHC I in the ER and is transported to the cell surface where it
interferes with CD8+ T cell recognition of MHC I (Kavanagh et al.,
2001b; Kleijnen et al., 1997). M6 redirects assembled MHC I:peptide
complex from the endoplasmic reticulum (ER) to the lysosome where
it is subsequently degraded (Reusch et al., 1999). M152 retains MHC I
in the ER/Golgi compartment, thus blocking plasma membrane
localization (Ziegler et al., 2000; Ziegler et al., 1997). The glycoproteins
encoded by the four HCMV ORFs, US2, US3, US6 and US11 have all
been associated with post translational blockade at several critical
steps in MHC I processing (Ahn et al., 1996). US2 and US11 inhibit cell
surface expression of MHC I and US3 and US6 both block peptide
loading by inhibiting tapasin and Transporter associated with Antigen
Processing (TAP).Fig. 1. Rat bone marrow derived DC cell surface marker expression. Immature DC cultures we
rats and cultured for 9 days in complete media plus GM-CSF and IL-4. Non-adherent cells wer
media without (A) and with (B) LPS. (A) Cells were analyzed by ﬂow cytometry for cell surf
OX42, OX62, and major histocompatibility marker complexes, MHC I (RT1A), and MHC II (
cytometry for cell surface expression of CD86, CD80, MHC I and II (RT1B). Isotype control (A critical component of the CMV life cycle is the ability of the virus
to replicate in MHC II positive cells, including endothelial cells,
epithelial cells, monocytes, macrophages and DCs (Fish et al., 1998;
Lockridge et al., 1999; Michelson, 1997). Infection of macrophage
progenitors is believed to play a pivotal role in viral dissemination and
reactivation from latent or low level persistent infections. While a
variety of mechanisms and virus-encoded ORFs that mediate MHC I
down regulation have been extensively studied, relatively little is
known about CMV induced MHC II down regulation. Four HCMV ORFs
have been identiﬁed as modulators of MHC II cell surface expression:
US2, US3, UL83 and UL111A (vIL10) (Chang et al., 2004; Hegde et al.,
2002; Tomazin et al., 1999). US2 modulates MHC II cell surface
expression by directly causing the degradation of HLA-DRα and
destabilizes newly formed MHC II α/β complex (17). US3 blocks
efﬁcient sorting of MHC II molecules to the peptide loading
compartment by binding class II α/β complexes, which compromises
the stability of those complexes (Hegde et al., 2002). In ﬁbroblasts
induced to express MHC II, UL83 and UV inactivated virus was shown
to down regulate cell surface HLA-DRα by an unknown mechanism
(Odeberg et al., 2003). Studies investigating vIL10 have demonstrated
that it is both a structural and functional homologue of cellular IL10,
however there are conﬂicting reports on the effectiveness of the viral
cytokine to down regulate cell surface MHC II (Kotenko et al., 2000).
For example, Raftery et al. have shown that vIL10 blocked LPS induced
MHC II cell surface expression in immature peripheral blood derivedre generated from total bone marrow cells isolated from the femurs of adult male Lewis
e removed by washing, and the remaining adherent DCs were incubated for 24 h in fresh
ace expression of CD8α, CD11b, CD11c, CD45R-B220, CD86 (B7.2), CD80 (B7.1), CD172a,
RT1B). Isotype control (grey). (B) Cells were analyzed at 24 h post treatment by ﬂow
grey), LPS treated cells (solid black), Mock treated-no LPS (dashed).
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effect on MHC II expression in mature PBDC (Chang et al., 2004;
Raftery et al., 2004). MCMV lacks an IL10 homologue, however, the
virus down regulates surface MHC II on primary macrophages and the
macrophage cell line, IC21 by inducing secretion of cellular IL10
(Redpath et al., 1999).
Several laboratories have outlined the impact of direct infection of
APCs on their ability to initiate both innate and adaptive immune
responses to CMV in vitro. Likewise, human DC function in the context
of a natural HCMV infection has also been analyzed (Frascaroli et al.,
2006; Varani et al., 2005a, 2005b). Circulating DC obtained from
patients undergoing active CMV infection were both phenotypically
and functionally impaired with a 50% reduction in MHC II (Frascaroli
et al., 2006). Furthermore, DC derived from heart transplant recipients
with acute CMV disease have reduced MHC II and diminished ability
to stimulate T cell proliferation (Varani et al., 2005a). The current
study utilizes a direct infectivitymodel of rat bonemarrow derived DC
(BMDC) to investigate RCMV-induced MHC manipulation. DC pro-
genitors are highly abundant in the bone marrow, easily accessible
and an important cell type in CMV biology. While RCMV has
previously been shown to transiently down regulate MHC I in
ﬁbroblasts, there are no published reports describing RCMV infection
of DC or the ability of the virus to manipulate MHC II. Here we
demonstrate that immature rat DCs are highly susceptible to RCMV
infection, and that infection of these cells, results in a greater than 90%
reduction in the levels of intracellular and cell surface MHC II. The
virus-induced depletion of MHC II is the result of direct infection,
requiring immediate early and/or early viral gene expression, is not
mediated by a secreted factor and appears to occur by at least twoFig. 2. Rat BMDCs are highly susceptible to RCMV infection. (A) BMDCs were infected 24 h p
bottom panels) for 48 h and then assessed by ﬂowcytometry for GFP expression. Gate numbe
RCMV-GFP at an MOI=0.1. At 48 h post-infection, the cells were ﬁxed with 1% paraformald
(blue), GFP (green). Mag=60×. C) Growth kinetics of RCMV-WT (squares) and RCMV-GFP (t
presence of virus (combined intracellular and extracellular) in the cultures was determined
forming units per ml and represent the average of three replicates.mechanisms: one affecting synthesis of nascent MHC II alpha, the
other degrading mature MHC II by acid dependent proteases.
Results
RCMV infection of rat bone marrow derived dendritic cells
Dendritic cells andmacrophages play an important role in immune
surveillance and CMV dissemination throughout the infected host, as
well as development and maintenance of latency and reactivation.
Previous reports utilizing peripheral blood derived DC and DC/APC
cell lines have demonstrated a limited susceptibility of in vitro
cultured murine and human DC to MCMV and HCMV infections,
respectively. Currently there are no published reports demonstrating
rat CMV (RCMV) infection of rat DCs. Therefore, we developed an in
vitro model using RCMV-infected BMDCs to examine the effects of
RCMV on DC immunobiology. In order to derive dendritic cell cultures,
bone marrow cells were cultured for 9 days in RPMI containing GM-
CSF (10 ng/ml) and IL4 (5 ng/ml) (Muthana et al., 2004). At 9 days,
the non-adherent cells were removed by washing, leaving only those
cells that were tightly adherent. The adherent BMDCs were fed fresh
media without cytokine and incubated for 24 h (hrs) in the presence
or absence of LPS.
BMDCs were analyzed by ﬂow cytometry for cell surface markers,
including CD8α, CD11b, CD11c, CD45R-B220, CD86 (B7.2), and CD80
(B7.1), CD172a, OX42, OX62, and major histocompatibility marker
complexes, MHC I (RT1A), and MHC II (RT1B). BMC cultured under
the conditions described above express classical dendritic cell markers,
including inherently high levels ofMHC I and II (Fig.1A). BMDC culturedost LPS treatment (mDC) or mock (iDC) at an MOI=1.0 (top panel) or 0.5 (middle and
rs represent the percent of the population positive for GFP. (B) BMDCwere infectedwith
ehyde, permeabilized and stained with anti-RCMV-IE antibody (red) and with Hoechst
riangles) in BMDCs. At the indicated time points after infection (days post-infection) the
by standard plaque assays on rat RFL6 ﬁbroblasts. Viral titers are expressed as plaque
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levels of costimulatorymolecules, CD80andCD86. BMC incubated in the
presence of LPS for 24 h had increased cell surface expression of CD86,
CD80,MHC I andMHC II relative tomock treated BMC (Fig.1B), which is
a characteristic of DC maturation (Muthana et al., 2004).
BMDCs were infected with either wild type RCMV (WT) or a
recombinant RCMV expressing GFP under an eF1α promoter in order
to mark the infected DC and compare the direct and indirect effects of
viral infection in infected versus uninfected cells from the same
culture. Immature and mature (LPS treated) BMDC were mock-
infected or infected with RCMV-WT or RCMV-GFP at a multiplicity of
infection (MOI) equal to 0.5 or 1.0. Infection was assessed by ﬂow
cytometry for GFP expression 48 h post-infection (hpi) (Fig. 2A).
Uninfected cells (mock) and those cells infected with a non-GFP
expressing RCMV (RCMV-WT) served as negative controls for
autoﬂuorescence. We found that rat BMDCs are highly susceptible to
RCMV infection. Greater than 90% of iDC were GFP positive when
infected at an MOI of 1.0 with RCMV-GFP. Fig. 2B demonstrates that all
of the GFP positive cells also stained positive by immunoﬂuorescenceFig. 3. RCMV down regulates MHC I and II cell surface expression. (A–C) iDCs were
infected at an MOI equal to 1.0 with either RCMV-Wt (thin black line), RCMV-GFP
(dashed black line) ormock (thick black line) for 48 h and surface stained for MHC I (A),
MHC II (RT1B) (B) or CD86 (C). Isotype controls were depicted with a thin grey line. In
panels D and E, iDCs infected with RCMV-GFP at an MOI=0.1 were stained for surface
expression of CD80 (D), or CD44H (E). Infected cultures were gated for GFP expression
[GFP positive cells (thin dashed line), GFP negative cells (thin black line), mock treated
cells (thick black line), and isotype controls (thin grey line)].
Fig. 4. RCMV infected BMDC are unable to induce allogeneic CD4 T cell proliferation in a
mixed leukocyte reaction. BMDC isolated from Lewis strain rats were infected with
RCMV-Wt for 72 h, and cocultured with CFSE labeled splenocytes taken from ACI strain
rats for 5 days. Non-adherent cells were stained with anti-CD4 Ab and analyzed by FACS.
CD4+ T cell proliferation was measured by CFSE dilution. T cell proliferation is
represented as the percent of total CD4+ T cells that have divided. Isotype control
(black ﬁll), Uninfected (dark grey ﬁll), RCMV-infected (white ﬁll). Shown in the right
panels are histograms demonstrating CFSE ﬂuorescence in CD4+ T cells mixed with
infected or uninfected DCs.for RCMV-Immediate Early proteins. In general, the infected cells
displayed high levels (mean ﬂuorescent intensities; MFI) of GFP
expression, however there were cells that displayed low but
detectable levels of GFP. Approximately 61% of iDC infected at an
MOI of 0.5 were GFP positive at 48 hpi. Infection of mDC at an MOI of
0.5 yielded a lower infectivity rate compared to iDC (40% GFP+). The
reduction in the total number of GFP positive cells coupled with the
44% reduction in MFI in infected mDC cultures compared to iDC
cultured in parallel suggests a reduced susceptibility of mDC to RCMV
infection relative to iDC. In the remainder of this study we further
examined RCMV infection of iDC.
To determine whether RCMV productively infects BMDCs, we
analyzed growth of the virus in these cells. For this experiment, DCs
were infected with RCMV-WT or RCMV-GFP at an MOI equal to 1 and
harvested at 1, 2, 3, 5, and 8 dpi. The samples were stored at −80 °C
until analysis. Titration of the combined cellular and supernatant
fractions was performed by standard plaque assays. Viral replication
was minimal in these cells, which mimics the growth of HCMV in DCs.
The amount of infectious virus from the infected DCs was similar for
both the RCMV-WT and RCMV-GFP viruses and the levels peaked at 3
dpi (Fig. 2C).
RCMV reduces expression of DC surface markers critical to
antigen presentation
DC induced activation of Tcells depends upon antigen presentation
in the context of both MHC and costimulatory molecules. To
investigate the effects of RCMV infection on antigen presentation
and DC activation, iDCs were infected at an MOI of 1.0 or 0.1 with
either RCMV-WT or RCMV-GFP. As shown in Fig. 3, cell surface
expression of the costimulatory molecules CD80 and CD86 as well as
MHC I and II was analyzed at 48 hpi by ﬂow cytometry. Infection of
iDCs resulted in a 94% and 89% drop in bothMHC II and I (respectively)
MFIs relative to uninfected cells (Figs. 3A and B). DC infected with
RCMV-WT and -GFP at an MOI equal to 1.0 displayed equivalent levels
of MHC on the cell surface, suggesting that the deletion of ORFs r145–
147 or the expression of eGFP does not affect RCMV-mediated down
82 C.C. Baca Jones et al. / Virology 388 (2009) 78–90regulation of MHC. CD44H, hyaluronic acid receptor, expression was
analyzed as a control for a possible viral induced global down
regulation of host cell surface markers (Fig. 3E). The levels of CD44H
were unchanged in infected versus uninfected cells. This ﬁnding
suggests that the RCMV-induced reduction in MHC expression is a
speciﬁc event and not the result of a global down regulation of cell
surface molecules.Fig. 5. Intracellular MHC II is undetectable in RCMV infected BMDC. (A) BMDCs were infected
isotype control antibody or antibodies directed against CD44H or MHC II (red). Deconvolu
infected with RCMV-Wt at an MOI=0.5. Cells were permeabilized and stained 48 hpi w
microscopy was used to visualize the stained cells. Mag=60×. (C) BMDCs were infected wi
48 h post-infection (lane 2). Uninfected rat RFL6 cells (lane 1) and uninfected BMDCs (lane 3
MHC II, RCMV-IE, or RhoA.Expression levels of the costimulatory molecules, CD80 and CD86,
were also examined as possible RCMV targets of the host cell antigen
presentation pathway. While uninfected iDCs maintained low level
CD86 expression, cells infected at an MOI=1.0 with either RCMV-WT
or -GFP up regulated surface expression of CD86 (Fig. 3C). Cell surface
expression of CD80 was examined in the context of RCMV-GFP
infection (MOI=0.1); iDCs from the infected culture were gated onwith RCMV-GFP. Cells were ﬁxed, permeabilized and stained 48 hpi with either an IgG
tion microscopy was used to visualize the stained cells. Mag=60×. (B) BMDCs were
ith Hoechst (blue), MHC II (green) and anti-RCMV-IE antibody (red). Deconvolution
th RCMV-WT at an MOI=1 and the cells were harvested in Laemmli's sample buffer at
) served as controls. Samples were analyzed byWestern blot analysis for the presence of
Fig. 6. RCMV induces a stable depletion of cell surface MHC I and II. (A) BMDC were
infected with RCMV-GFP at an MOI=0.1 and harvested at the times indicated for
analysis via FACS. Uninfected cells were harvested in parallel at the indicated times.
Isotype control (grey line), Uninfected cells (thick black line), RCMV-infected, GFP
positive cells (thin black line), BMDC from the same infection culture but uninfected,
GFP negative (dashed black line). (B) Western blot analysis of MHC II depletion in
RCMV-infected BMDC. BMDC were infected with RCMV-WT at an MOI=1 and the cells
were harvested in Laemmli's sample buffer at the indicated time points after infection.
Uninfected rat RFL6 cells and uninfected BMDCs served as controls. Blots were stained
for MHC II, RCMV-IE or GAPDH.
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reduced to isotype control levels, while uninfected (GFP negative)
cells had slightly elevated levels of the costimulatory molecule
compared to cells from uninfected cultures (Fig. 3D). The dramatic
reduction in cell surface expression of MHC I, II and the costimulatory
molecule CD80 to isotype control levels in RCMV-infected BMDC
suggests a speciﬁc targeting of the host cell antigen presentation
pathway. The increased expression of CD86 and static level of CD44H
in infected BMDC further suggests that the loss of MHC and CD80 is
not the result of a universal down regulation of cell surface marker
expression, but rather a speciﬁc viral strategy aimed at subversion of
the host cell adaptive immune response.
RCMV infection of iDC blocks CD4 T cell proliferation in an allogeneic
mixed leukocyte reaction
To determine the impact of RCMV-mediated down regulation of
cell surface MHC II on DC function as antigen presenting cells, mixed
leukocyte reactions were performed on infected versus uninfected
iDCs. CD4 Tcell proliferation (asmonitored by CFSE dilution)was used
as a measure of CD4 T cell activation. BMDC were generated, as
described above, from Lewis strain rats. These cells were mock-
infected or infected with RCMV-WT for 72 h at MOI=1.0, and then
incubated with CFSE labeled splenocytes isolated from the allogeneic
rat strain ACI. BMDC and splenocytes were cocultured for 5 days
before analysis by ﬂow cytometry. Non-adherent cells were taken
from the culture and stained for CD4. Tcell proliferationwasmeasured
as a loss of CFSE intensity. Data is represented as the percent of total
CD4+ cells that proliferated. A greater than 20-fold reduction in T cell
proliferation was observed in the allogeneic T cells added to the
infected iDC cultures compared to the uninfected cells (Fig. 4). This
ﬁnding suggests that iDCs infected with RCMV are functionally
impaired and lack the ability to induce T cell proliferation.
RCMV depletes both cell surface expression and intracellular MHC II in DCs
To determinewhether the RCMV-induced down regulation of MHC
II surface levels was due retention of these molecules in intracellular
compartments, we assessed the total levels of MHC II in infected iDCs
by immunoﬂuorescence staining andwestern blotting. BMDC infected
with RCMV-GFP at an MOI=1.0 were ﬁxed and permeabilized at
48 hpi. Cells were stained for MHC II and visualized by epiﬂuorescence
using a deconvolution microscope. The infected, GFP positive, iDC had
undetectable levels of MHC II staining, while GFP negative cells in the
same ﬁeld of view showed both a diffuse cytoplasmic and concen-
trated plasma membrane staining for MHC II (Fig. 5A). The GFP
positive cells stained similarly for CD44H compared to uninfected
cells. Immunoﬂuorescence images shown in Fig. 5B of iDC infected
with RCMV-WT further conﬁrm the RCMV-GFP IF staining. BMDC
were infected at an MOI=0.1. Infected cells were stained for IE
(green) and MHC II (red). The absence of MHC II in IE positive cells is
in agreement with the reduction of detectable MHC II in RCMV-GFP
positive cells. The mutually exclusive staining patterns of MHC II and
RCMV-IE/GFP is consistent with the ﬂow cytometry data in which cell
surface levels of MHC II were nearly undetectable in infected iDC.
Similarly, DCs infected with RCMV were completely devoid of MHC II
as determined by western blot analysis (Fig. 5C).
RCMV-mediated MHC down regulation occurs at a post-transcriptional
step
To determine the kinetics of the RCMV-mediated down regulation
of MHC I and II, a time course analysis of MHC staining following virus
infection was undertaken. For this experiment, in order to identify
infected vs. uninfected cells within the same culture, RCMV-GFP was
used to infect iDC at an MOI=0.1. Cells were analyzed for surfaceexpression levels of MHC I and II at 12, 24, 48, and 72 hpi, and gated on
GFP expression to examine direct effects of RCMV infection and GFP
negative cells to study indirect effects. The virus-mediated MHC II
down regulation becomes detectable between 12 and 24 hpi (Fig. 6A).
However, the most striking drop in MHC II cell surface expression
84 C.C. Baca Jones et al. / Virology 388 (2009) 78–90occurs at 24 hpi (83% drop in MFI of infected versus uninfected cells),
which corresponds to the timing of early viral gene expression. By
72 hpi cell surface levels approach isotype control levels indicating
that RCMV infection stably removes MHC II to background levels. The
kinetics of MHC I down regulation is delayed in comparison to MHC II.
Cell surface levels drop in the infected cells between 24 and 48 hpi,
further declining (greater than 40% reduction) by 72 hpi (Fig. 6A).
Importantly, MHC I and II are only down regulated in the GFP positive
(infected) cells suggesting that this effect is actively mediated by virus
infection and not a soluble factor found within the inoculum or
secreted as a result of infection.We also analyzed total levels of MHC II
by western blotting at 12, 24, 36, 48, and 72 hpi in order to determine
whether the kinetics of the observed degradation of total MHC II
corresponds to the decrease in surface expression. As shown in Fig. 6B,
initially at 12 hpi MHC II is slightly up regulated in the infected
cultures. However, MHC II degradation begins between 24 and 36 hpi
occurring at the time of the reduction in surface expression. By 48 hpi
the levels have dropped by 90%. This data demonstrates that the
reduction in MHC II surface expression corresponds to a similar
reduction in total cellular MHC II levels.
To elucidate the mechanisms of RCMV-mediated down regulation
of MHC, we determined the effects of RCMV infection on MHC
transcription and translation. To determine whether RCMV infectionFig. 7. RCMV infection does not alter gene expression of MHC I and II in rat BMDCs. RT-PCR
infected rat BMDC at 12, 24, and 36 hpi (n=3). RT-PCR TaqMan detectionmRNA from the gen
chase analysis was performed in mock- and RCMV-infected BMDC at 24 hpi. Cells were star
pulse, cells were diluted in chase media containing an excess of cold cysteine and methionine
by lysing the cell pellets in lysis buffer. MHC II was immunoprecipitated using the indicated a
washed and resuspended in sample buffer and analyzed by SDS-PAGE and visualized by auto
lactacystin (50 μM) for 36 h. Cells were harvested in sample buffer at 36 h post treatment. Un
MHC II RT1B and GAPDH. Pulse chase analysis was performed in mock- and RCMV-infected B
Cells were starved and then labeled with 35S-methionine/cysteine at 0.2 mCi/ml for 10 min
and methionine and then washed. Cells were then chased for 1 h at 37 °C and then harves
indicated antibody for 1 h at 4 °C, followed by a 2 h incubation with Protein A/G beads. B
visualized by autoradiography. A fraction of the cellular lysate for each sample was also proaffects transcription of MHC in BMDC, we used quantitative RT-PCR
TaqMan to compare the mRNA levels of MHC I and II at 12, 24, and
36 hpi. The expression of both MHC I and II was slightly elevated at
12 hpi. However, by 24 hpi the levels of gene expression returned to
those levels observed in uninfected cells (Fig. 7A). This ﬁnding
indicates that RMCV infection does not affect the transcription of
MHC. Therefore, since a massive depletion of MHC II occurs in the
infected cells beginning at 24–36 hpi, we next explored whether
RCMV modulated translation of MHC II. For this assay, BMDC were
infected with RCMV for 24 h and thenmetabolically labeled in a pulse-
chase experiment and the cellular lysates were immunoprecipitated
with antibodies directed against MHC II and analyzed by SDS-PAGE.
The pre-glycosylated form of MHC II was present in the pulse samples
for both the uninfected and infected cell lysates (Fig. 7B). However,
there was a reduction in the accumulation of labeled MHC II in the
RCMV-infected BMDCs. This was accompanied by a similar reduced
level of MHC II in the chase of the infected cells. In order to establish
whether this down regulation was mediated by the proteasome,
epoxomicin was used to treat the cells prior to and during the pulse-
chase. Western blots to measure the increase in poly-ubiquitinated
species upon proteasome inhibition was used to conﬁrm the effective
concentration of lactacystin and epoxomicin in the rat BMDCs (Fig.
7C). Epoxomicin treatment did not affect MHC II protein levelsTaqMan was used to detect expression of MHC I and MHC II in uninfected and RCMV-
e for the ribosomal protein L32 was used to normalize the expression data (n=4). Pulse
ved and then labeled with 35S-methionine/cysteine at 0.2 mCi/ml for 10 min. After the
and thenwashed. Cells were then chased for 0.5, 1, 2 or 3 h at 37 °C and then harvested
ntibody for 1 h at 4 °C, followed by a 2 h incubation with Protein A/G beads. Beads were
radiography. Western blot analysis of Ub in BMDC treated with epoxomicin (100 nM) or
treated BMDCs (mock) served as controls. Blots were stained for ubiquitinated proteins,
MDC cultures treated with or without the proteosomal inhibitor epoxomicin (100 nM).
. After the pulse, cells were diluted in chase media containing an excess of cold cysteine
ted by lysing the cell pellets in lysis buffer. MHC II was immunoprecipitated using the
eads were washed and resuspended in sample buffer and analyzed by SDS-PAGE and
bed by western blotting for GAPDH to ensure equal loading.
85C.C. Baca Jones et al. / Virology 388 (2009) 78–90observed in both the pulse and chase samples from the uninfected or
infected cells (Fig. 7D). This suggests that while there is a post-
transcriptional reduction in MHC II it is not mediated by proteasomal
degradation.
RCMV degradation of MHC II is inhibited by increasing
endosome/lysosomal pH
While the post-transcriptional effect onMHC II synthesis in RCMV-
infected cells at 36 hpi suggests a mechanism for the sustained
reduction, this mechanism would not be sufﬁcient for the rapid
degradation of MHC II occurring by 24 hpi. We reasoned that one
possible mechanism for this massive depletion of cell surfaceMHC II is
through increased recycling and degradation in the infected cells. To
test this hypothesis, we performed western blot analysis for MHC II in
cellular lysates from infected and uninfected BMDCs treated at 12 hpi
with baﬁlomycin for an additional 36 hpi. Baﬁlomycin inhibits the
proton pump associated with endosomes and lysosomes ultimately
inhibiting the pH sensitive proteinases found in these vesicles.
Baﬁlomycin inhibited the degradation of MHC II observed in the
infected cells (Fig. 8A). Baﬁlomycin also increased accumulation of
MHC II in uninfected cells. Interestingly, a SDS-stable form of MHC II
was only detected in the baﬁlomycin treated RCMV-infected BMDCs.
To conﬁrm the effect of baﬁlomycin on preventing RCMV-mediated
MHC II degradation and to visualize the cellular location of MHC II
accumulation, we visualized immunoﬂuorescence stained uninfected
and RCMV-infected BMDCs with and without baﬁlomycin treatment
by deconvolution microscopy. For this assay, BMDCs were infected
with anMOI=0.5 to ensure that at least 50% of the cells were infected.
As demonstrated above, MHC II was present in the uninfected cells but
not in the GFP+ infected BMDCs in the same culture (Fig. 8—lower
panel). However, MHC II was observed in the infected cells whenFig. 8. RCMV down regulation of MHC II is sensitive to treatment with baﬁlomycin. Weste
(100 nM). BMDC were infected with RCMV-WT at an MOI=1 for 12 h, treated with drug fo
served as controls. Blots were stained for MHC II RT1B and then the blot was stripped and p
baﬁlomicin (100 nM) for an additional 36 h. Cells were ﬁxed at 48 hpi, permeabilized and st
Infection was detected by GFP expression (green). Deconvolution microscopy was used to vtreated for 24 h with baﬁlomycin. In these cells MHC II was
predominantly in large vesicles suggesting that RCMV promotes the
recycling of MHC II, which is then degraded in an endocytic or
lysosomal compartment.
RCMV down regulation of MHC I and II requires IE/E gene expression
While we show above that RCMV-mediated MHC down modula-
tion only occurs in the infected cell, this process could be mediated by
a number of factors including a cellular response to RCMV binding and
entry, a component of the virion itself used in a post-entry step, or a
protein encoded in the viral genome requiring viral replication for
expression. To determine whether virus replication was necessary for
MHC down regulation, BMDC were infected at an MOI=1.0 with
either RCMV-WT or UV inactivated RCMV-WT from the same viral
preparation. Infected and mock treated cells were examined 48 hpi by
ﬂow cytometry for the presence of MHC I and II (Fig. 9A). MHC I cell
surface expression was slightly increased (MFI equal to 103 versus
uninfected MFI equal to 71.1) in cells infected with UV inactivated
virus, while MHC II levels were relatively unchanged (MFI=70.1)
compared to uninfected cells (MFI=79.8). These data demonstrate
that neither a component of the viral inoculum, a protein component
of the virion itself, nor viral binding/entrymediate the effect observed
on MHC down regulation induced by RCMV infection.
Next, we determined whether late viral gene expression was
required to induce MHC down regulation. RCMV-infected iDCs were
treated with Foscarnet, an inhibitor of RCMV DNA synthesis, which
blocks virus late gene expression and viral replication. MHC I and II
cell surface levels were reduced regardless of Foscarnet treatment in
the infected cells and were unaffected in mock-infected cells (Fig. 9B).
Although basal levels of MHC II (on uninfected iDC) were reduced in
cells treated with Foscarnet, versus uninfected untreated iDC,rn blot analysis of MHC II depletion in RCMV-infected BMDC treated with baﬁlomicin
r an additional 36 h and then harvested in sample buffer at 48 hpi. Uninfected BMDCs
robed for GAPDH. BMDCs were infected with RCMV-GFP for 12 h and then treated with
ained with antibodies directed against MHC II RT1B (red) and Hoechst DNA dye (blue).
isualize the stained cells. Mag=60×.
Fig. 9. RCMV induced reduction in MHC I and II expression is not mediated by viral
binding and entry, late gene expression or by a secreted factor. (A) BMDC were infected
at anMOI=1with RCMV-Wt (thin black line) orWt-UV inactivated (dashed black line)
or mock-infected (thick black line) for 48 h and analyzed by FACS for cell surface
expression of MHC I and II. Isotype control (grey). (B) BMDC were pretreated with
Foscarnet or mock, and then infected at an MOI equal to one with RCMV-Wt. Isotype
control (grey), Uninfected+Foscarnet (thick black line), Infected+Foscavir (thin black
line), Infected— Foscarnet (dashed black line). (C) BMDC were infected with RCMV-Wt
(thin black line) or mock (thick black line), or conditioned supernatants from RCMV-
infected BMDCs (dashed black line), for 48 h and then assessed for cell surface
expression of MHC II. Isotype control (grey line), RCMV-Wt infected (thin black line),
uninfected (thick black line), conditioned supernatant treatment (dashed black line).
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reduce the level of cell surface MHC II (by greater than 65%). The
continued loss of MHC expression in the presence of Foscarnet
suggests that RCMV-induced MHC depletion is not mediated by late
viral gene transcription. Together, these results support the hypothesis
that the RCMV-induced depletion of MHC I and II is mediated by a viral
immediate early or early gene product.
Soluble factors do not mediate RCMV-induced MHC down regulation
Previous studies investigating HCMV and MCMV induced MHC II
manipulation have implicated both a viral homologue of IL10 (UL111a)
and the induction of cellular IL10, respectively (Chang et al., 2004;
Redpath et al., 1999; Spencer et al., 2002). Since the RCMV genome
lacks an UL111a homologue, a possible role for cellular IL10 or other
secreted factors in the modulation of MHC II surface expression was
explored. For this experiment, supernatants collected from RCMV-WT
infected iDC were clariﬁed by ultracentrifugation and these cell- and
virus-free supernatants were incubated with uninfected iDC for 48 h.Surface levels of MHC II were slightly elevated in cells treated with
supernatants from infected cells compared to those cells treated with
supernatants from uninfected DC (Fig. 9C). One could argue that a
soluble factor released by an infected cell may have a limited stability
in culture. If this were true, onewould predict that the uninfected cells
within the same infected DC culture would also down regulate MHC II
from the cell surface. However, that is not the case since uninfected
cells from low MOI infected cell cultures, wherein not all of the cells
are infected, do not down regulate MHC molecules from their surface
(shown in Figs. 3E and 6A). As an added control for whether virus-
derived or -induced cellular secreted IL10 mediated the effect on MHC
down regulation, infected and uninfected cells were incubated with
saturating concentrations of a neutralizing antibody to rat IL10. Both
infected and uninfected cells treated with anti-IL10 neutralizing
antibody failed to elicit any signiﬁcant changes in their MHC levels
compared to antibody-untreated cultures. These ﬁndings in combina-
tionwith our lowMOI experiments presented in Figs. 3E and 6A argue
against a soluble factor causing the depletion of MHC molecules from
RCMV-infected DC.
Discussion
In the current report an RCMV/DC infection systemwas utilized to
explore the effects of CMV infection on DC function. We demonstrate
for the ﬁrst time that rat BMDC are highly susceptible to RCMV and
that infection signiﬁcantly down regulates surface levels of CD80,
MHC I andMHC II, while other cell surface markers such as CD44H are
not down regulated suggesting that the effect is speciﬁc for a subset of
cell surfacemarkers. A greater than 90% reduction of MHC II from both
the cell surface and intracellular pools in RCMV-infected rat DCs was
observed. The signiﬁcance of the loss of MHC and the costimulatory
molecule, CD80, was underscored when a functional impairment in
DC mediated antigen presentation was conﬁrmed in a mixed
leukocyte reaction. RCMV does not affect MHC transcription but
may have a small effect on translation at a post-transcriptional step.
The RCMV-mediated degradation of MHC II was inhibited by the
ATPase/proton pump inhibitor baﬁlomycin, suggesting that the virus
promotes destruction of MHC II in endosomes/lysosomes by cellular
or viral pH-dependent proteases. Unlike MCMV, the RCMV-mediated
reduction of MHC was not caused by secreted factors since super-
natants from infected cells failed to induce a reduction in MHC surface
expression. Furthermore, when cells infected at lowMOI (equal to 0.1)
with RCMV-GFP were gated for GFP expression, only the GFP positive
cells were depleted of MHC II. In the same infected DC culture the
uninfected GFP negative cells had high levels of MHC II. Viral
replication (and not a viral structural protein) was required for the
down regulation of MHC I and II as DCs infected with UV inactivated
RCMV displayedMHC levels that paralleled uninfected cells. The effect
on MHC I and II surface expression was mediated by an immediate
early or early gene, other than R145–147, since both the treatment
with Foscarnet (inhibits late viral gene expression) and infectionwith
the RCMV-GFP(ΔR145–147) virus failed to block the down regulation.
The high susceptibility of the DC to infection coupled with the stable
and near complete loss of MHC all highlight the RCMV-BMDC
infection model as an extremely useful tool to study the role of CMV
infection in the down regulation of MHC II.
MHC I down regulation is likely the most widely used means of
viral immune evasion occurring in both RNA and DNA viruses. Down
regulation of MHC I in CMV infected cells eliminates CTL recognition of
infected ﬁbroblasts in vitro (Pinto et al., 2006). Although a dramatic
enhancement in viral ﬁtness in vivo remains to be linked directly to
MHC I depletion, blockade of CD8+ Tcell surveillance is likely to assist
in viral persistence or reactivation from latency in a particular cell
type, as seen during HSV reactivation from latency (Liu et al., 2000). In
this report we demonstrate that RCMV dramatically reduces MHC I
surface expression to near background levels. A previous study by
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expression on the surface of RCMV-infected ﬁbroblasts (Hassink
et al., 2005). However, the effects of RCMV infection on MHC I
expression as reported by Hassink et al. were modest and transient,
occurring only at 12 hpi. Here we demonstrate that RCMV infection
causes a massive down regulation of MHC I surface expression in
infected dendritic cells. While this is not the ﬁrst report to
demonstrate that RCMV infection affects MHC I surface levels, the
data outlined in this study are consistent with the effects observed in
HCMV, RhCMV, and MCMV infected cells. It is unclear why such a
dramatic surface down regulation of MHC I occurs in RCMV-infected
DCs but not in ﬁbroblasts, however the distinct effects may reﬂect the
differences in the cell types used for these assays.
While viral interference with the MHC I antigen presentation
pathway has long been recognized as an adaptive strategy to evade
CD8+ T cell recognition, the advantage of viral subversion of the MHC
II pathway has only recently been the subject of investigation. MHC II
is typically associated with the exclusive presentation of extracellular
antigen, and presentation of viral antigen is more commonly
associated with intracellular MHC I presentation, however, manipula-
tion of MHC II could provide at least two advantages to a long-term
persistent virus such as CMV. First, blockade of MHC II would inhibit
APC triggering of the adaptive arm of the immune system in response
to phagocytosed infected cells (extracellular antigen). Second, it has
been demonstrated that intracellular CMV antigen may be presented
in the context of MHC II during an active infection of class II expressing
cells (Hegde et al., 2005). The build up of viral glycoproteins within
the trans Golgi network or acidic compartments in preparation for
viral assembly may lead to a leakage of endogenous viral antigen into
the MHC II compartment. CMV induced MHC II blockade is likely to be
advantageous to establishing a persistent infection in both its ability
to evade detection during a primary infection of an APC and the ability
to suppress the CD4+ T cell responses including the downstream
production of antibodies.
Interestingly, RCMV differentially affected expression of the
costimulatory molecules, CD80 and CD86. RCMV down regulated
surface expression of CD80 while CD86 surface expression was
elevated in the infected cells. MCMV and HCMV infection of
macrophages or DCs causes the down regulation of both of these
molecules (Loewendorf et al., 2004; Mintern et al., 2006; Moutaftsi
et al., 2002). Although ligation of CD28 on T cells by either CD80 or
CD86 can provide the needed “second stimulus” required to activate
naïve T cells, recent reports support a functional duality in CD80
versus CD86 ligation. A role for CD80 in the development of a Th1
response has been identiﬁed, particularly enhancing CTL effector
function, whereas CD86 ligation stimulates naïve T cells to differ-
entiate into Th2 cells (enhancing among other things antibody and
IL10 production) (Kuchroo et al., 1995; Lang et al., 2002). Differential
regulation of CD80/86 expression in RCMV-infected APCs, may further
shift the balance in favor of viral persistence by inducing a tolerizing
state in the host immune response.
One of the most striking features of the RCMV-BMDC model
system is the degree of MHC II depletion in infected dendritic cells. At
72 hpi, RCMV-infected BMDC have a greater than 84% reduction in
MHC II cell surface MFI compared to uninfected BMDC. Furthermore,
intracellular MHC II was below the limit of detection by immunos-
taining in cells infected for 48 h, indicating that in addition to the lack
of MHC II on the cell surface it is either rapidly destroyed in the
infected DC and/or RCMV blocks the synthesis of MHC II, however, the
mechanisms remain to be elucidated. Reductions inMHC II cell surface
expression ranging from 15 to 50% have been reported for HCMV-
infected human monocyte derived DC and MCMV infected mouse DC
(Andrews et al., 2001; Mathys et al., 2003; Moutaftsi et al., 2002;
Raftery et al., 2001; Varani et al., 2005b). Whether the variation in the
degree of MHC depletion is due to speciﬁc differences in the origin of
the cells, the differentiation state of the cells, the distinction betweenHCMV and MCMV lab-adapted strains compared to a more wild type
strain of RCMV, or simply due to an RCMV-speciﬁc phenomena,
remains to be elucidated. However, CMV may have a more dramatic
effect on MHC II down regulation in DC derived from bone marrow
versus DC derived from peripheral blood monocytes, which under-
scores the importance of these cells in CMV pathogenesis. In any case,
the RCMVmodel system provides a unique opportunity to explore the
mechanisms and impact of CMV induced MHC II manipulation in the
context of infection, which has previously proven problematic using
the HCMV in vitro model systems. In fact, most of our knowledge
about HCMV-mediated MHC II manipulation comes from studies that
employed U373 cells transfected with the MHC constitutive transac-
tivator, MIITA, to produce high levels of MHC II. Similarly, the study
identifying UL83 as a modulator of MHC II utilized a system in which
MHC II negative ﬁbroblasts were induced to express the molecule
upon stimulation with IFNγ (Odeberg et al., 2003). In these studies,
isolated expression of UL83, US2 and/or US3 mediated the down
regulation of MHC II in these induced expression systems (Hegde
et al., 2002; Odeberg et al., 2003; Tomazin et al., 1999). Similarly,
HCMV infection of these cells also caused a signiﬁcant decrease in
MHC II expression. However, the degradation of MHC II was only
decreased by about one-third when the MIITA transfected U373 cells
were infected with a recombinant strain of HCMV (RV7186) lacking
the IRS1-US11 region of the genome, suggesting that other regions of
the genome were also involved in down regulating MHC II (Cebulla
et al., 2002). These ﬁndings highlight the importance of developing
direct infection-based systems for the identiﬁcation of the full
complement of CMV genes involved in the modulation of MHC II.
A speciﬁc MCMV ORF that mediates MHC II down modulation has
yet to be identiﬁed, however, both MCMV and HCMV have been
shown to down regulate MHC II surface expression by inducing
cellular IL10 (Nordoy et al., 2003; Redpath et al., 1999). HCMV also
encodes a viral homologue of cellular IL10, cmvIL10 (UL111A), which is
a structural and functional homologue of the cellular version (Chang
et al., 2004; Kotenko et al., 2000; Lockridge et al., 2000; Raftery et al.,
2004). Due to the inefﬁcient infection rate of monocyte derived DC
with HCMV, studies examining the effects of both cellular and viral
IL10 have been performed with recombinant proteins and by
transferring infected ﬁbroblast conditioned supernatants onto DCs
(Chang et al., 2004; Raftery et al., 2004). The effects of neither cellular
nor cmvIL10 on MHC II expression in DCs has been explored in the
context of an actual HCMV infection. In contrast to the ability of
conditioned supernatants from HCMV and MCMV infected cells to
transfer the effect of MHC II down regulation, we demonstrate in this
report that RCMV conditioned supernatants alone do not depleteMHC
II in uninfected DCs. The failure of RCMV cultured supernatants to
modify MHC II was further substantiated when using the RCMV-GFP
virus. In these experiments, GFP positive cells were low in MHC II
expression, whereas GFP negative cells from the same infection
culture expressed high levels of MHC II. Taken together, these results
suggest the absence of a paracrine effect in RCMV-induced MHC II
down regulation. Studies investigating MHC II surface expression in
macrophages shortly following HCMV infection found that infection
with UV inactivated virus depleted MHC II surface expression
(Odeberg et al., 2003; Odeberg and Soderberg-Naucler, 2001). Further
examination of this effect in IFN-γ stimulated ﬁbroblasts identiﬁed
UL83 (pp65), the ORF encoding a prominent virion component, as a
mediator of MHC II surface depletion in ﬁbroblasts (Odeberg et al.,
2003). While RCMV encodes a UL83 homologue, we show that the
effect of MHC II down regulation in rat BMDC did not occur in cells
infected with UV inactivated virus. In addition, RCMV is not known to
encode sequence homologues to the other three ORFs identiﬁed as
MHC II modulators in HCMV, US2 US3, and UL111a suggesting an
additional mechanism by which RCMV infection of DCs blocks MHC II
surface expression and facilitates the degradation of intracellularMHC
II (Hegde et al., 2002; Tomazin et al., 1999).
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CMV manipulation due to its importance in coordinating the adaptive
antiviral response, MHC II down regulation may have additional
consequences in CMV induced disease. For example, the fact that CMV
remains latent in myeloid lineage cells destined to become profes-
sional antigen presenting cells suggests that the effect onMHC II could
have an important role in reactivation from latency. In addition, in
vascularized solid organ and bone marrow transplantation HCMV
seropositivity has long been identiﬁed as a major contributing factor
in graft rejection (McLaughlin et al., 2002). Our previous work
showing that recipient immune response to allogeneic donor tissue is
required for RCMV acceleration of transplant vascular sclerosis, the
primary indicator of vascularized graft rejection, further highlights the
interplay between the host immune system and CMV infection during
transplant rejection (Orloff et al., 2002). Of particular interest is a
recent study demonstrating that a subset of dendritic cells presenting
alloantigen in the context of MHC II mediates allograft tolerance
(Ochando et al., 2006). The presentation of alloantigen by a subset of
DC facilitated the generation of alloantigen speciﬁc regulatory T cells,
which mediate graft tolerance (Ochando et al., 2006). Human DC
derived from patients undergoing active CMV infections are function-
ally impaired at inducing T cell responses and express higher levels of
proinﬂammatory cytokines (Frascaroli et al., 2006; Varani et al.,
2005a). Our ﬁnding that RCMV infection of BMDC nearly eliminates
MHC II from the cell surface, taken together with the work of other
groups suggests a possible mechanism by which RCMV accelerates
allograft rejection by elimination of MHC II from the surface of
infected DC diminishing their capacity to stimulate the development
of regulatory T cells critical to maintaining tolerance to the donor
tissue (Frascaroli et al., 2006; Ochando et al., 2006; Varani et al.,
2005a). The alteration of suppressor T cell development could tip the
immune system from a state of tolerance to a state that enhances
allograft rejection.
In summary, bone marrow derived DCs are highly susceptible to
RCMV infection, and the process of active viral infectionmodulates the
ability of these infected cells to mediate an effective immune
response. As demonstrated in this report, the RCMV-BMDC infection
model provides three advantages to the study of CMV infection of DC
and the effect on CMV disease. First, the infection model will facilitate
the identiﬁcation of novel RCMV ORFs mediating CMV inducedMHC II
manipulation. The ﬁnding of previously unrecognized RCMV gene
products affecting MHC II may lead to the discovery of both functional
and sequence homologues in HCMV and MCMV. Second, the high rate
of infection of BMDCs with RCMVwill facilitate mechanistic studies of
CMV induced depletion of MHC II in infected DC. Third, the RCMV-
BMDC model systemwill permit the investigation of CMV infection of
DC and their possible role in graft rejection. A thorough analysis of the
RCMV genes and mechanisms of MHC II down regulation will be
imperative to dissect the role of Class II depletion in HCMV-infected
individuals.
Materials and methods
Generation of bone marrow derived DCs
Rodents were housed in the AAALAC accredited Portland VA
Medical Center animal facility in a speciﬁc-pathogen-free room in
compliance with USDA/HHS guidelines. Bone marrow was ﬂushed
from the femurs and tibias of Lewis and F344 adult male rats and
strained through a 70 μm ﬁlter. Bone marrow cells were washed twice
in complete RPMI-1640 medium supplemented with 10% v/v fetal
bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM
L-glutamine. Bone marrow cells were then cultured at a cell density of
1×106 cells per ml in complete RPMI supplemented with 10 ng/ml
recombinant rat GM-CSF (R&D Systems, 518-GM) and 5 ng/ml
recombinant rat IL4 (R&D Systems), in a ﬁnal volume of 10 ml. Fivedays after plating, the cells were given fresh media plus GM-CSF and
IL-4. Nine days after initial plating, the non-adherent cells were
removed from the culture; adherent cells were washed three times
with DPBS, once with RPMI and then cultured in complete RPMI
without cytokine. In order to stimulate the immature BMDCs to
mature, the cells were treated with 1 μg/ml LPS. After an additional
24-hour incubation, the LPS-matured or immature BMDC were
washed twice with DPBS and once with RPMI, and then cultured in
complete RPMI.
Rat cytomegalovirus
Tissue culture-derived stocks of the Maastricht strain of RCMV
were ampliﬁed and titered in rat lung ﬁbroblasts (RFL6). Cell free virus
was obtained from the cultured supernatants of infected cells, which
were spun at 2 k RPM for 20 min to remove cell debris, and then
pelleted at 22 k RPM (Beckman SW28) through a sorbitol cushion
(20% D-sorbitol, 0.05 M Tris, 1 mM MgCl2). The virus pellet was
resuspended in Minimal Essential Medium (MEM) culture media.
Plaque assays were performed in conﬂuent 24-well plates by infection
with an appropriate serial virus dilution in 0.2 ml of media and then
incubated at 37 °C for 3 h. Following incubation, the infected cells
were overlaid with 1 ml MEM supplemented with 10% fetal bovine
serum (FBS), non-essential amino acids, pen/strep and 20 mM L-
Glutamine with carboxymethylcellulose (Sigma, St. Louis, MO). After
7 days, the cells were ﬁxed in 3.7% formalin in PBS and stained with
0.05% aqueous methylene blue (Sigma). The plaques were counted by
light microscopy. To inactivate RCMV replication, the required pfu of
infectious virus was diluted in serum-free medium in 10 cm dish and
exposed for 4 min at 999 mJ/cm2 in a UV-Crosslinker (Fisherbrand-
UVXL-1000), which we have previously determined as sufﬁcient to
inactivate 100% of RCMV replication in ﬁbroblasts using immunos-
taining at 24 hwith antibody to IE gene product. In addition, the RCMV
DNA polymerase inhibitor, Foscarnet (0.5 mM) was used to treat
infected cell cultures at 8 h post-infection in order to determine
whether the effect of the RCMV down regulation of MHC was due to
the expression of a late viral gene product.
Construction of RCMV-GFP
To mark infected cells, we constructed a recombinant RCMV strain
(RCMV-Δ145-7GFP), in which the ORFs r145, r146 and part of r147
were deleted and replaced by homologous recombination with a GFP
expression cassette. The recombination plasmid pΔR145-7 was
constructed as follows. A 1 kb region of RCMV from 196,976 to
197,998 (RB1) was produced by PCR with the primers r144Fwd: ata
aag ctt atc gcg gac gcg gac agc gag ata t and r144Rev: ata gat ctt taa tta
acg gga ttg aga tat acg tac acc gtg and cloned into pCDNA-3 using the
restriction enzymes HindIII and NotI. The primers for the second PCR
fragment from 200,771 to 201,803were r147Fwd: ata tta att aat gta tca
ggc acc gtg tac tcg ata acg and r147Rev: ata gcg gcc gca agc ttg agg tag
aag tag aat aaa gcg tta tga. The second fragment (RB2) was cloned into
pCDNA-3Δr144 using NotI and XhoI. The GFP cassette was blunt end
inserted into the Not1 site found in pCDNA-3Δr144-7. The EF-1α/
eGFP cassette from the vector pQ100 (a gift from Dr. J. Vieira,
University of Washington) was cut with EcoRV/XhoI and blunt ended
for subsequent cloning into the recombination vector to make
pΔR145-7. Since the primer r147 Rev also contained an internal
HindIII site, this enzyme was used to release a 3.5 kb fragment
containing the RCMV ﬂanking regions and GFP cassette.
The virus was constructed by transfecting HindIII cut pΔR145-7
into 1×106 RFL-6 cells (260 kV, 975 μFarrads) with a GenePulser
(BioRad). The cells were plated in complete DMEM for 6 h and then
infected with 1×105 PFU of salivary gland-derived RCMV. After two
days the cells were scraped, and cells and supernatants were frozen at
−80 °C. The mix was thawed and added to fresh RFL-6 cells. On the
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dilution on RFL-6 cells in 96-well plates (4 times). The integrity and
clonal purity of the recombinant virus were conﬁrmed by restriction
endonuclease digestions in combination with Southern blot analysis
(data not shown).
Antibodies
The following primary antibodies were used for phenotypic analysis
of BMDCs and splenocytes: MHC II [RT1.B] (Serotec, MRC OX-6),
(Serotec, OX-17), MHC I [RT1.A] (Serotec, OX-18), CD80 (Serotec, 3H5),
CD86 (Serotec, MRC OX-48), CD44H (BD Pharmingen, OX-49), CD8α
(BDPharmingen,OX-8), CD11b (Serotec, OX-42), CD11c (Serotech, 8A2),
CD45R (BD Pharmingen, HIS24), CD172a (Serotec, OX-41), OX-62
(Serotec, MRC OX-62), IL10 (PeproTech Inc., 500-P139), RhoA (Santa
Cruz, sc-179) and GAPDH (AbCAM, ab8245). The following secondary
antibodies were used: anti-mouse IgG APC (eBiosciences, 17401282),
donkey anti-rabbit HRP (Amersham, NA934V), swine anti-goat HRP
(Biosource, ACI 3404), anti-mouse HRP (Amersham, NXA-931). Isotype
Controls: IgG2a (BD Pharmingen, 553454), IgG1 (BD Pharmingen,
550615), and IgG1 (BD Pharmingen, 557273).
Flow cytometry
BMDCs were removed from plastic dishes with gentle scraping,
and spun at 2 k RPM for 5 min to pellet. The pelleted cells were
washed in DPBS one time, resuspended at a cell density of 1×107 cells
per ml in FACS Block Buffer (20% Normal Goat Serum in Dulbecco's
Phosphate Buffered Saline, 0.1% NaN3) and incubated on ice for
20min. Blocked cells were spun at 2 k RPM for 5 min and resuspended
in FACS Wash Buffer (1% NGS in DPBS, 0.01% NaN3) at 1×107 cells per
ml. A total of 1×106 cells were stained with each appropriate primary
antibody for 30 min on ice. Following primary antibody incubation,
cells were washed three times with FACS Wash Buffer and resus-
pended in 200 μl FACS Wash Buffer and incubated with the
appropriate secondary antibody or streptavidin-allophycocyanin (BD
Pharmingen, 554067) for 30min on ice. The stained cells werewashed
twice with FACS Wash Buffer and analyzed on a FACS Calibur (Becton
Dickinson) utilizing Cell Quest software. Final data analysis was
performed using FlowJo software (Tree Star, Inc.).
Immunoﬂuorescence microscopy
BMDC samples were cytospun (Shandon) onto glass slides, which
were subsequently washed with PBS and ﬁxed with 2% PFA in PBS. For
intracellular staining, the samples were permeablized and blocked in
intracellular staining buffer (ISB: 1 g BSA, sodium azide, 0.5% Triton-
X100, and 500 ml PBS) with 10% normal goat serum (NGS) for 20 min.
The primary antibodies (diluted in ISB) directed against MHC II,
CD44H, and RCMV-IE were incubated for 2 h at room temperature. IgG
isotype antibodies were used as a negative staining control. Samples
were washed with ISB and incubated with ﬂuorescein isothiocyanate
(FITC) or L-rhodamine conjugated secondary anti-mouse or anti-
rabbit antibodies (BioSource International, Camarillo, CA), diluted in
ISB for 1 h. Samples were washed with ISB, mounted and visualized
using a Delta Vision RT microscope by Applied Precision. Photomicro-
graphs were obtained at 60× magniﬁcation.
Western blot
Total cell lysates from mock-infected iDC or iDC infected at an
MOI=1 treated with and without epoxomicin (100 nM) or baﬁlo-
mycin (10 μM) were run on 12% polyacrylamide SDS-PAGE gels.
Proteins were transferred to PVDF membrane (Millipore). The blots
were blocked with 5% milk in DPBS, and then incubated with the
indicated primary antibody. Membranes were washed with TrisBuffered Saline plus 0.2% Tween 20 (TBS-T), incubated with the
corresponding HRP conjugated secondary antibody, and washed with
TBS-T. The proteins were visualizedwith the Advance ECLWestern Blot
Detection Kit (Amersham, RPN2135) and autoradiography. Protein
levels were normalized to GAPDH or RhoA.
Mixed leukocyte reaction
Lewis rat BMDCs were prepared as described above and mock-
infected or infected at an MOI equal to 1.0 with WT RCMV. Allogeneic
splenocytes were prepared from macerated whole spleens harvested
from ACI strain rats, washed three times in sterile DPBS and labeled
with CFSE (CellTrace CFSE Cell Proliferation Kit, Molecular Probes) per
manufacturer's instructions. Labeled splenocytes were cocultured
with mock- or RCMV-infected BMDCs (72 hpi) at a 1:1 ratio for ﬁve
days and then stained for CD4. T cell proliferation was measured as a
function of CFSE dilution in the CD4+ cell population by ﬂow
cytometry.
Metabolic labeling, proteasome inhibition
BMDCs were gently scraped from the plates at 24 hpi, washed
twice in DPBS and incubated for 1 h at 37 °C in starvation media
(Hepes buffered RPMI without cysteine or methionine). Following
starvation, cells were pulsed with 35S-methionine/cysteine (Perkin
Elmer, Easy Tag 35S protein labeling mix) at 0.2 mCi/ml for 20 min.
After the pulse, cells were diluted in chase media containing an excess
of cold cysteine and methionine and then washed two times with ice
cold PBS. Cells were then chased for the indicated times at 37 °C.
Samples treated with inhibitor were incubated with either 100 nM
epoxomicin (Peptides International, IEP-4381-V) or 50 μM lactacystin
(Sigma, L6785) throughout the starvation, pulse, and chase periods.
Immunoprecipitation
Cell pellets were lysed on ice in lysis buffer (0.5% NP-40, 50 mM
Tris HCl pH 7.4, 5 mMMgCl2, 1 mM PMSF, 150 mM NaCl plus protease
inhibitors). Lysates were preabsorbed with Protein A/G agarose beads
preincubated with 2 μg IgG isotype control Ab for 30 min at 4 °C. After
the 30 min incubation the bead/lysate mixture was spun at 10 k RPM
for 5 min and the cleared supernatant transferred to fresh Eppendorf
tube containing 2 μg of the indicated antibody and rotated for 1 h at
4 °C, followed by a 2 h incubationwith Protein A/G beads. Beads were
washed four times with PBS, pelleted and resuspended in Laemelli's
buffer and analyzed by SDS-PAGE and visualized by autoradiography.
Quantitative RT-PCR detection of MHC I and MHC II
Total RNAwas prepared from uninfected and infected BMDC using
the Trizol method (Gibco BRL) at 12, 24 and 36 hpi. cDNA was
generated using Superscript III RT (Invitrogen) and analyzed by real-
time PCR techniques using primer sets recognizing MHC I RT1A (fwd:
ACAGATCACCCGGAACAAGTG, rev: ATCTGCGGAGCGACTCCAC), MHC II
RT1B (fwd: ACAACCTGCTGGTCTGCTCA, rev: TCCCCGTTCCTAATAAGC-
TGTG), and L32 (fwd: GAAGATTCAAGGGCCAGATCC, rev: GTGGACCA-
GAAACTTCCGGA). Primers sets were identiﬁed using Primer Express
software (Applied Biosystems). RT-PCR reactions were performed
using the SYBR Green PCR Master Mix (Applied Biosystems).
Following thermal activation of AmpliTaq Gold (10 min at 95 °C), a
total of 40 cycles were performed (15 s. at 95 °C and 1 min at 58 °C)
using the ABI Prism 7700 Sequence Detection System (Applied
Biosystems). Plasmid clones containing each gene fragment were
used as positive controls and quantiﬁcation standards. PCR results
were analyzed using ABI Prism 7700 Sequence Detection Software.
The sensitivity of detection of this assay was b100 plasmid copies for
the tested genes. The ribosomal subunit, L32, was used to normalize
90 C.C. Baca Jones et al. / Virology 388 (2009) 78–90the expression data. Quantitative PCR data were analyzed by ANOVA
and student's t-test.
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